New drug combination kick-starts immune system to fight cancer
Researchers from The School of Cancer & Pharmaceutical Sciences have found a way to boost the immune system to help it fight back against cancer. The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together, help kick start the body’s natural defences.
The advance, which is published in the journal Clinical Cancer Research today, involves the targeting of an enzyme called Heme Oxygenase-1 (HO-1), which is active in a variety of cancers. HO-1 can promote the growth of tumours by preventing the immune system from effectively attacking cancer cells.
Scientists have already shown in the laboratory that chemotherapy can trigger immune responses against cancer, but the King’s team have found that these responses are suppressed by non-tumour cells called ‘macrophages’, which reside in the tumour and produce the HO-1 enzyme.
In a major breakthrough, researchers found that in preclinical trials, a drug being tested for the treatment of jaundice (SnMP), effectively prevented the suppression of the immune response stimulated by chemotherapy, allowing the immune system to efficiently attack the cancer. The authors suggest that inhibiting HO-1 with SnMP shares many similarities with ‘checkpoint inhibitor’ antibody drugs, a new group of therapies, the first of which are now in routine use in cancer clinics around the world.
The report’s authors, Dr James Arnold and Professor James Spicer, are working with Cancer Research UK to develop these observations into a first-in-human clinical trial for this combination treatment. Speaking about the breakthrough Dr Arnold said: “In lab tests SnMP plus chemotherapy combination compared favourably to the current checkpoint inhibitor therapy used in the clinic, suggesting that there could be significant scope for targeting HO-1 in patients.
“The full benefit to patients will be better understood once we move these exciting observations into clinical trials. However, in our preclinical models, when combined with chemotherapy, the efficacy of tumour control was comparable to that of the ‘gold-standard’ immuno-therapy currently being used in the clinic.
“We are hopeful that our research will represent a new drug class and combination treatment that will help to awaken the immune system to attack cancer."
Funders
Preclinical research work was funded by the European Research Council and Cancer Research UK.
About King’s College London
For further information about King's, please visit the King's in brief web pages.
World-changing ideas. Life-changing impact: https://spotlight.kcl.ac.uk/
About King's Health Partners
Collectively, King’s Health Partners is the largest provider of cancer services in London and one of the largest in England. Between the partners - King’s College London and Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts - the full spectrum of clinical cancer care, pioneering research and excellent training is provided across our sites. The partnership was awarded Comprehensive Cancer Centre status by the Organisation of European Cancer Institutes (OECI) in October 2015, and Cancer Research UK Centre status in December 2016. In September 2016 a new state-of-the-art Cancer Centre at Guy’s Hospital opened where clinicians, trials coordinators and researchers work side by side to deliver high quality patient care. The Cancer Centre also includes a King’s College London research floor – the Innovation Hub – so that frontline clinicians and researchers work side by side to the benefit of patients.
About Cancer Research UK
For further information about Cancer Research UK's work or to find out how to support the charity, visit www.cancerresearchuk.org.